No abstract

No abstract

This is a prepublication version of an article that has undergone peer review and been accepted for publication but is not the final version of record. This paper may be cited using the DOI and date of access. This paper may contain information that has errors in facts, figures, and statements, and will be corrected in the final published version. The journal is providing an early version of this article to expedite access to this information. The American Academy of Pediatrics, the editors, and authors are not responsible for inaccurate information and data described in this version.

, persons aged <18 years accounted for approximately 11% of 28.4 million reported COVID-19 cases in the United States*; however, data on pediatric infections with SARS-CoV-2, the virus that causes COVID-19, are limited (1). Surveys of SARS-CoV-2 antibody seroprevalence suggest that cumulative incidence of infection is much higher than that ascertained by reported COVID-19 cases (2,3). Evidence of previous SARS-CoV-2 infections among young persons in Mississippi was assessed by testing for antibodies to SARS-CoV-2 on a convenience sample of residual serum specimens collected for routine testing by an academic medical center laboratory during May 17-September 19, 2020. Seroprevalence by calendar month was standardized to the state population by race/ethnicity; cumulative numbers of infections were estimated by extrapolating seroprevalence to all persons aged <18 years in Mississippi. Serum specimens from 1,603 persons were tested; 175 (10.9%) were positive for SARS-CoV-2 antibodies. Among 1,579 (98.5%) specimens for which the race/ethnicity of the person tested was known, specimens from 16 (23.2%) of 69 Hispanic persons, 117 (13.0%) of 901 non-Hispanic Black persons, and 30 (5.3%) of 565 non-Hispanic White persons tested positive. Populationweighted seroprevalence estimates among persons aged <18 years increased from 2.5% in May to 16.3% in September 2020. Based on these estimates, 113,842 (95% confidence interval [CI] = 90,096-153,652) persons aged <18 years in Mississippi might have been infected with SARS-CoV-2 by mid-September 2020. The number of COVID-19 cases reported in this age group through August 31, 2020 was 8,993. Serosurveys that include pediatric age groups can help provide evidence of cumulative disease incidence, estimate frequency of undiagnosed cases of SARS-CoV-2 among young persons, and guide prevention efforts. Most persons who are infected with SARS-CoV-2 develop antibodies to SARS-CoV-2 proteins within 1-2 weeks of disease onset (4). Serologic testing for SARS-CoV-2 antibodies, albeit having imperfect sensitivity and specificity, † is useful to identify past SARS-CoV-2 infections. Serology tests are

No abstract